HIPEC for Colorectal Cancer With Peritoneal Carcinomatosis

Video

This video reviews the use of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer with peritoneal carcinomatosis.

Peritoneal carcinomatosis, present in about 10% to 15% of colorectal patients at the time of diagnosis, is difficult to detect by imaging and often only discovered intraoperatively.

In this video, Hans Schlitt, MD, of the University of Regensburg Medical Center in Germany, discusses the use of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery in this setting, which in selected patients is associated with improved survival.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content
Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Perioperative Chemo Improves Survival, Control in Esophageal Cancer

Perioperative Chemo Improves Survival, Control in Esophageal Cancer

Tim Cortese
July 19th 2025
Article

Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.

Encorafenib Combo Earns Chinese Approval in BRAF V600E+ Metastatic CRC

Russ Conroy
July 13th 2025
Article

Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.